PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak`s anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with treatment-naïve wet (neovascular) age-related macular degeneration (AMD). `Treating the first patients in this pivotal study is an important step for Kodiak as we grow the company and accelerate our efforts with KSI-301,` said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. `On World Sight Day, we...
|
